Exicure 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Paul Kang

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	1.3yrs
CEO 소유권	n/a
경영진 평균 재임 기간	1.3yrs
이사회 평균 재임 기간	1.3yrs

최근 관리 업데이트

Recent updates

CEO

Paul Kang (62 yo)

1.3yrs

테뉴어

Mr. Paul Kang is Director of Exicure, Inc. from February 24, 2023 and serves as its Chief Executive Officer since August 21, 2023 and has been its President. He is associated with CBI USA Inc. Mr. Kang beg...

리더십 팀

이름	위치	테뉴어	보상	소유권
Paul Kang	CEO, President & Director	1.3yrs	데이터 없음	데이터 없음
Jiyoung Hwang	CFO, Secretary & Director	1.3yrs	데이터 없음	데이터 없음
Joshua Miller	Chief Accounting Officer	1.5yrs	데이터 없음	0.011% € 3.7k

1.3yrs

평균 재임 기간

48yo

평균 연령

경험이 풍부한 관리: 2H0 의 관리팀은 경험 (평균 재직 기간 1.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Paul Kang	CEO, President & Director	1.8yrs	데이터 없음	데이터 없음
Jiyoung Hwang	CFO, Secretary & Director	1.8yrs	데이터 없음	데이터 없음
Michael Hodges	Member of Advisory Board	no data	데이터 없음	데이터 없음
Amy Paller	Member of Advisory Board	no data	데이터 없음	데이터 없음
Henry Paulson	Member of Advisory Board	4.9yrs	데이터 없음	데이터 없음
Hojoon Lee	Director	1.3yrs	데이터 없음	데이터 없음
Hyuk Ko	Independent Director	1.3yrs	데이터 없음	데이터 없음
Dongho Lee	Independent Director	1.3yrs	데이터 없음	데이터 없음
Minhee Eom	Independent Director	1.2yrs	데이터 없음	데이터 없음

1.3yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 이사회: 2H0 의 이사회는 경험(평균 재직 기간 1.3 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Exicure 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

High number of new and inexperienced directors

Exicure, Inc. Appoints Anna Chukaeva as Senior Vice President, Head of Corporate Development and Bioinformatics

Exicure, Inc., Annual General Meeting, Jun 28, 2024

No independent directors

Exicure, Inc. Appoints Minhee Eom to the Board

Exicure, Inc. Announces Executive Changes

Recent updates

Exicure Request for Subsequent Extension to Nasdaq Hearings Panel Till December 17

Nasdaq Hearings Panel Grants Exicure Extension for Continued Listing on The Nasdaq Capital Market, Compliance Required by November 14, 2024

Exicure Regains Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Exicure Announces 1-for-5 Reverse Stock Split to Regain Compliance with Nasdaq’s Listing Rules

High number of new and inexperienced directors

Exicure, Inc. Appoints Anna Chukaeva as Senior Vice President, Head of Corporate Development and Bioinformatics

Exicure Receives Positive Listing Determination from Nasdaq

Exicure Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(b)(1)

Exicure, Inc., Annual General Meeting, Jun 28, 2024

Exicure, Inc. Receives Nasdaq Notice of A Delisting Determination

Exicure, Inc. announced delayed 10-Q filing

Exicure, Inc. announced delayed annual 10-K filing

New minor risk - Financial data availability

No independent directors

Exicure Receives Non-Compliance Notice From Nasdaq

Exicure Receives Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Exicure, Inc. announced delayed 10-Q filing

Exicure, Inc. Appoints Minhee Eom to the Board

Exicure Receives Non-Compliance Notice From Nasdaq

Exicure, Inc. Announces Executive Changes

Less than half of directors are independent

Exicure Notifies Nasdaq Regarding Continued to be Not in Compliance with Rule 5605(c)(2)(A)

Exicure Receives Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

CBI USA Inc Sends a Letter to Exicure Inc

Exicure, Inc. announced delayed 10-Q filing

No independent directors

Exicure, Inc. Announces Resignation of Jeffrey L. Cleland from the Board of Directors, Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

Exicure Receives Notice from Nasdaq Regarding No Longer in Compliance with Nasdaq's Independent Director and Audit Committee Requirements

Exicure, Inc. Announces Resignation of Jiyoung Hwang from the Board of Directors

Exicure, Inc. Announces Executive Changes

Exicure, Inc. Contemplates Bankruptcy

Exicure, Inc. announced that it expects to receive $5.44 million in funding from CBI Inc.

Exicure Receives Noncompliance Notice from Nasdaq

Second quarter 2022 earnings released

Exicure Regains Compliance with Nasdaq Minimum Bid Price Requirement

Exicure Announces Receipt of Nasdaq Notice of Non-Compliance

First quarter 2022 earnings released: US$0.069 loss per share (vs US$0.14 loss in 1Q 2021)

Exicure, Inc. announced that it expects to receive $5.040289 million in funding from CBI USA, Inc, Abingworth LLP

High number of new and inexperienced directors

Exicure, Inc., Annual General Meeting, May 27, 2022

Exicure, Inc. Announces Executive, Board and Committee Changes

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Exicure, Inc. Investors

Exicure Receives A Letter from the Staff Nasdaq Stock Market

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Exicure, Inc

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.049 loss in 2Q 2020)

Exicure, Inc.(NasdaqCM:XCUR) dropped from Russell Microcap Value Index

Exicure, Inc. Advances Clinical and Pre-Clinical Pipeline Designed to Bring Therapies to Patients with Unmet Medical Needs

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.013 profit in 1Q 2020)

Co-Founder & Director Chad Mirkin has left the company

Exicure, Inc. Announces Spherical Nucleic Acid Technology Shows Promising Results in Phase 0 Trial in Patients with Glioblastoma

Full year 2020 earnings released: US$0.28 loss per share (vs US$0.46 loss in FY 2019)

Revenue misses expectations

Exicure, Inc. Announces David R. Walt Did Not Stand for Re Election

Exicure Announces Appointments of Board of Directors

New 90-day high: €2.06

Exicure Appoints James Sulat to Board of Directors

Exicure, Inc. Announces That the U.S. Food and Drug Administration (Fda) Has Granted Fast Track Designations for Its Clinical Product Candidate

New 90-day high: €1.66

Exicure, Inc. Announces Executive Changes

New 90-day low: €1.22

Third quarter 2020 earnings released: US$0.10 loss per share

Revenue beats expectations

Exicure, Inc. Announces Resignation of Helen S. Kim as A Class II Director

Exicure Presents Updates Phase 1b Data from the Ongoing Phase 1B/2 Clinical Trial Evaluating Intratumoral Cavrotolimod

New 90-day low: €1.24

New 90-day low: €1.39

Exicure, Inc. Announces Executive Changes, Effective September 30, 2020

New 90-day low - €1.55

New 90-day low - €1.70